ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Authors
Keywords
ABC transporters, multi-drug resistance , ADME-Tox, tyrosine kinase inhibitors, molecular targeted anticancer therapy
Journal
PHARMACEUTICAL RESEARCH
Volume 31, Issue 9, Pages 2237-2255
Publisher
Springer Nature
Online
2014-05-20
DOI
10.1007/s11095-014-1389-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sunitinib Reverse Multidrug Resistance in Gastric Cancer Cells by Modulating Stat3 and Inhibiting P-gp Function
- (2013) Ye Zhang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells
- (2012) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
- (2012) Wen-jing Zhou et al. BRITISH JOURNAL OF PHARMACOLOGY
- Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models
- (2012) Amit K. Tiwari et al. CANCER LETTERS
- Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
- (2012) Suneet Shukla et al. DRUG RESISTANCE UPDATES
- Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents
- (2012) S. Agarwal et al. MOLECULAR CANCER THERAPEUTICS
- The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
- (2012) R. Sen et al. MOLECULAR CANCER THERAPEUTICS
- Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
- (2012) Selvi Durmus et al. MOLECULAR PHARMACEUTICS
- Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas
- (2012) Victor Hugo Villar et al. PLoS One
- Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics
- (2011) B. Poller et al. DRUG METABOLISM AND DISPOSITION
- Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
- (2011) Anna Brózik et al. Expert Opinion on Drug Metabolism & Toxicology
- Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer
- (2011) Taroh Satoh et al. INVESTIGATIONAL NEW DRUGS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- 5,7-Dimethoxyflavone and Multiple Flavonoids in Combination Alter the ABCG2-Mediated Tissue Distribution of Mitoxantrone in Mice
- (2011) Guohua An et al. PHARMACEUTICAL RESEARCH
- Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
- (2011) Yun-Ju Chen et al. PLoS One
- Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro
- (2011) Stefan Balabanov et al. PLoS One
- Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
- (2011) Xing-Xiang Peng et al. Chinese Journal of Cancer
- Experience with sorafenib and adverse event management
- (2010) Joaquim Bellmunt et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia
- (2010) Frank Boschelli et al. EUROPEAN JOURNAL OF CANCER
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
- (2010) H. Kodaira et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain
- (2010) S. Agarwal et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- Multiple Drug Resistance Mechanisms in Cancer
- (2010) Bruce C. Baguley MOLECULAR BIOTECHNOLOGY
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP
- (2010) J. Perry et al. MOLECULAR CANCER THERAPEUTICS
- Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
- (2010) J. S. Lagas et al. MOLECULAR CANCER THERAPEUTICS
- Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
- (2009) C Lemos et al. BRITISH JOURNAL OF CANCER
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function
- (2009) Li-yang Tao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences
- (2009) Amalia Azzariti et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
- (2009) Chun-ling Dai et al. CANCER LETTERS
- Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib
- (2009) Kohji Noguchi et al. CANCER SCIENCE
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- Doxorubicin: The Good, the Bad and the Ugly Effect
- (2009) Cristina Carvalho et al. CURRENT MEDICINAL CHEMISTRY
- The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
- (2009) L. Zhou et al. DRUG METABOLISM AND DISPOSITION
- Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors
- (2009) Wayne L. Furman et al. JOURNAL OF CLINICAL ONCOLOGY
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
- (2009) D K Hiwase et al. LEUKEMIA
- Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
- (2009) A. Morabito et al. ONCOLOGIST
- Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human
- (2009) Mark S. Warren et al. PHARMACOLOGICAL RESEARCH
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
- (2008) C.-l. Dai et al. CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic Considerations for New Targeted Therapies
- (2008) SD Baker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
- (2008) Gergely Szakács et al. DRUG DISCOVERY TODAY
- An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)
- (2008) J. W. Polli et al. DRUG METABOLISM AND DISPOSITION
- Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
- (2008) S. Shukla et al. DRUG METABOLISM AND DISPOSITION
- Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases
- (2008) Alfonso Quintás-Cardama et al. Future Oncology
- The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib
- (2008) Roos L. Oostendorp et al. INVESTIGATIONAL NEW DRUGS
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice
- (2008) S. Marchetti et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cisplatin: a review of toxicities and therapeutic applications
- (2008) K. Barabas et al. Veterinary and Comparative Oncology
- ABC multidrug transporters: structure, function and role in chemoresistance
- (2007) Frances J Sharom PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started